Skip to content

African-Americans with HIV have higher risk of aggressive kidney disease

Higher CD4 cell counts associated with lower rate of non-HIV-related diseases in patients taking antiretrovirals

Reducing d4T dose improves mitochondrial toxicity, but not lipoatrophy

Abacavir remains an equal first for people starting HIV treatment in US

Protease inhibitors increase fibrinogen levels: increased risk for hardening of the arteries

GSK says its abacavir trials show no heart attack risk

Start anti-HIV treatment with a CD4 cell count of 350 with efavirenz and Truvada, say draft British guidelines

HLA-B*5701 test for abacavir hypersensitivity works equally well in black and white patients

Most patients have a trusting relationship with their doctor after starting HIV drugs